Genmab Completes $1.8 Billion Acquisition of ProfoundBio | Visen Pharma Prepares for HK IPO
Sunday, 7 April 2024, 10:30
Genmab Acquires ProfoundBio
In a remarkable development, Copenhagen's Genmab A/S has successfully acquired Seattle-based ProfoundBio in a $1.8 billion all-cash transaction. This acquisition is poised to redefine the landscape of the ADC biotech sector.
Visen Pharma's IPO Plans
Shanghai's Visen Pharma has revealed plans to conduct an initial public offering on the Hong Kong Exchange, setting the stage for potential market expansion and increased investor interest in the biotech industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.